Comparison of single copy gene-based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19-directed CAR T cells in treated patients

MARIA-LUISA SCHUBERT1, CAROLINA BERGER2, ALEXANDER KUNZ1, ANITA SCHMITT1, ANITA BADBARAN2, BRIGITTE NEUBER1, SILKE ZESCHKE2, LEI WANG1, KRISTOFFER RIECKEN2, ANGELA HÜCKELHOVEN-KRAUSS1, INGO MÜLLER3, CARSTEN MÜLLER-TIDOW1,4, PETER DREGER1,4, NICOLAUS KRÖGER2, FRANCIS A. AYUK2, MICHAEL SCHMITT1,4 and BORIS FEHSE2

1Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, D-69120 Heidelberg; Departments of 2Stem Cell Transplantation and 3Pediatric Hematology and Oncology, University Medical Centre Hamburg-Eppendorf, D-20246 Hamburg; 4German Cancer Consortium, German Cancer Research Center/National Center for Tumor Diseases, D-69120 Heidelberg, Germany

Received December 3, 2021; Accepted February 11, 2022

DOI: 10.3892/ijo.2022.5338

Abstract. Chimeric antigen receptor (CAR) T cell therapy with axicabtagene ciloleucel, tisagenlecleucel and brexucabtagen ciloleucel has been adopted as the standard of care for patients with refractory and/or relapsed CD19-positive lymphoid malignancies. Monitoring of kinetics of CAR T cells after administration is crucial for patient follow-up and important to guide clinical decisions for patients subjected to CAR T cell therapy. Information of transgene copies within a CAR T cell product prior to administration, i.e. vector copy numbers, is of high importance to warrant patient safety. However, experimental assays for quantitative CAR T cell monitoring in the open domain are currently lacking. Several institutions have established in-house assays to monitor CAR T cell frequencies. In the present study, the quantitative (q)PCR assay established at the Heidelberg University Hospital (Heidelberg, Germany), i.e. single copy gene-based duplex qPCR, was compared with the digital droplet PCR assay established at the University Medical Center Hamburg-Eppendorf (Hamburg, Germany). Both methods that were independently developed enable accurate and comparable CAR T cell frequency assessment and are useful in the clinical setting.

Introduction

Cellular immunotherapy with CD19-directed chimeric antigen receptor (CAR) T cells is altering the treatment landscape of lymphoid malignancies. CARs are composed of an extracellular antigen-specific domain derived from an antibody's single chain variable fragment (scFv), a hinge and transmembrane segment and an intracellular domain to activate and co-stimulate the T cell expressing the CAR. In contrast to physiologic T cell receptors (TCRs), CARs are able to recognize unprocessed extracellular antigens and may therefore act in a human leukocyte antigen-independent manner. The intracellular CAR domain defines the different CAR generations: First-generation CARs contain only the tyrosine-based ζ-signal-transducing subunit from the TCR/CD3 receptor complex (1). Second-generation CARs carry costimulatory domains, e.g. CD28 or 4-1BB (CD137), adjacent to the
TCR/CD3ζ-domain. Costimulation has been indicated to enhance CAR T cell activity and has resulted in improved clinical efficacy compared to first-generation CAR T cells (2).

In 2018, two second-generation CAR T cell products, i.e. axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) were approved by the European Medicines Agency (EMA) for the treatment of patients with relapsed and/or refractory (r/r) B-cell lymphoid malignancies (3-6). While axi-cel, carrying CD28 as a costimulatory domain, has been approved for the treatment of patients with r/r diffuse large B cell lymphoma (DLBCL) and primary mediastinal B cell lymphoma (7), tisa-cel, carrying 4-1BB as a costimulatory domain, has been approved for the treatment of patients with r/r DLBCL and patients with r/r acute lymphoblastic leukemia (ALL) below 26 years of age (8). In 2020, the EMA approved the third CD19-directed CAR T cell product in Europe, i.e. brexucabtagene autoleucel (brexu-cel), for the treatment of patients with r/r mantle cell lymphoma (9). The CAR construct of brexu-cel is identical to axi-cel, but the two products differ in their manufacturing process, as brexu-cel includes the selection of T cells to exclude circulating malignant B-cells prior to T cell transduction. All three CAR T cell products are generated from autologous cells and are indicated for the respective underlying disease after two or more lines of therapy.

Quantification of CAR T cells and monitoring of CAR T cell kinetics are crucial diagnostic variables in patients treated with CAR T cells, as clinical response and toxicity have been indicated to depend on CAR T cell engraftment, expansion and persistence (10-16). Hence, the assessment of CAR T cell frequencies by widely available and easily applicable CAR T cell monitoring assays is important.

However, to date, precise and fast assays that enable the quantification of commercially available CAR T cells have been largely unavailable. Recently, our groups developed PCR-based in-house assays to detect and quantify CD19-directed CAR T cells (17-20). However, systematic comparison of different approaches for CAR T cell quantification has remained an open task, and it requires to be elucidated whether different PCR approaches with diverse technical elements and methodical parameters, i.e. quantitative PCR (qPCR) (19,20) and digital PCR (17,18), are able to provide comparable data when assessing CAR T cell frequencies. To address this, the qPCR assay established at the Heidelberg University Hospital (UKHD), i.e. single copy gene-based duplex qPCR (SCG-DP-PCR) (20), from here onwards referred to as qPCR, was compared to the digital droplet PCR (dPCR) assays established at the University Medical Center Hamburg-Eppendorf (UKE) (17,18). Both methods target the FMC63 sequence of the CAR (24) and digital PCR (17,18), are able to provide comparable data when assessing CAR T cell frequencies. To address this, the qPCR assay established at the Heidelberg University Hospital (UKHD), i.e. single copy gene-based duplex qPCR (SCG-DP-PCR) (20), from here onwards referred to as qPCR, was compared to the digital droplet PCR (dPCR) assays established at the University Medical Center Hamburg-Eppendorf (UKE) (17,18). Both methods target the FMC63-based scFv that is incorporated within the CD19-directed CAR T cells commercially available in Europe, i.e. axi-cel, tisa-cel and brexu-cel.

Materials and methods

Patient samples. Samples for CAR T cell quantification were obtained from a total of 20 patients, i.e. 10 patients with axi-cel and tisa-cel, respectively, at different time-points until up to six months after CAR T cell treatment. Each 10 patients had been treated at the UKHD or the UKE in accordance with the institutional guidelines (see Table I). Informed consent had been obtained from all patients prior to CAR T cell treatment and the study was approved by the local ethics committees at the UKHD (Heidelberg, Germany; no. S-254/2016) and UKE (Hamburg, Germany; no. PV7091).

Response to treatment was assessed according to revised response criteria for malignant lymphoma (21) or according to standard criteria for ALL (22). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded according to the consensus guidelines defined by the American Society for Transplantation and Cellular Therapy (23).

Genomic DNA (gDNA) was extracted from peripheral blood mononuclear cells (PBMCs) as described in the following and samples of gDNA were exchanged between the two institutions in a blinded manner. Quantification was performed using qPCR (20) at the UKHD and dPCR (17,18) at the UKE. Overall, 113 genomic DNA samples, 56 from patients treated with axi-cel and 57 from patients treated with tisa-cel, were analyzed.

qPCR at the UKHD. SCG-DP-PCR relies on the simultaneous amplification of the FMC63 sequence of the CAR (24) and the human SCG ribonucleosome (RNAse) P RNA component H1 (RP1H1; in the following referred to as RNaseP) as the internal standard. The following primer and probe sets were used: i) Primer/probe reaction mix (cat. no. 4331348; Applied Biosystems; Thermo Fisher Scientific, Inc.) targeting the FMC63 sequence of the CAR (24): Forward primer, TGAACACTGCGGAGTGCAAGA; reverse primer, CTG AGACAGTGCATGTGACGG; probe, FAM-CTGGCCCTG TGCCGCCCTCA-minor groove binder/non-fluorescent quencher; ii) RP1H1 (RNaseP) primer/probe reaction mix (cat. no. 4403326; TaqMan; Applied Biosystems; Thermo Fisher Scientific, Inc.) was used as described previously (19,20).

SCG-DP-PCR was performed on gDNA isolated from PBMCs. PBMC isolation was performed by Ficoll density gradient (Linaris GmbH) following the manufacturer’s protocol, washed and suspended in PBS.

gDNA was extracted using a commercially available DNA extraction kit and following the manufacturer’s instructions (cat. no. 51104; QIAamp DNA Blood Mini; Qiagen GmbH). The concentration of extracted gDNA was measured using UV spectroscopy (NanoDrop OneC; Applied Biosystems; Thermo Fisher Scientific, Inc.) targeting the internal standard. The following primer and probe sets were used: i) Primer/probe reaction mix (cat. no. 4331348; Applied Biosystems; Thermo Fisher Scientific, Inc.) targeting the FMC63 sequence of the CAR (24): Forward primer, TGAACACTGCGGAGTGCAAGA; reverse primer, CTG AGACAGTGCATGTGACGG; probe, FAM-CTGGCCCTG TGCCGCCCTCA-minor groove binder/non-fluorescent quencher; ii) RP1H1 (RNaseP) primer/probe reaction mix (cat. no. 4403326; TaqMan; Applied Biosystems; Thermo Fisher Scientific, Inc.) was used as described previously (19,20).

The following amplification conditions were used (19,20): 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. Thermal cycling was performed using a StepOnePlus real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.).
The calculation of copy numbers via qPCR was performed applying a $2^{-\Delta\Delta C_t}$ calculation method as previously described using the following formula (19,20): 

$$\text{Copy number/µm PBMC DNA} = 2^{-\Delta (C_{FMC63} - C_{RNaseP})} \times 2 \times 140,370.$$

dPCR at the UKE. gDNA from patient samples was prepared as previously described (17,18). In brief, PBMCs were isolated by Ficoll gradient centrifugation using SepMate (Stemcell Technologies, Inc.) following the manufacturer's protocol, washed and suspended in PBS. If available, ~1x10^6 PBMCs (in 200 µl) were loaded on columns of the QIA-Amp Blood Kit (Qiagen GmbH) and genomic DNA was isolated following the manufacturer's protocol. DNA was eluted in a final volume of 200 µl. If <1x10^6 mononuclear cells were available, all cells were used for DNA preparation and the elution volume was adjusted accordingly.

Typically, 100 ng gDNA from patient samples was prepared as previously described (17,18). In brief, PBMCs were isolated by Ficoll gradient centrifugation using SepMate (Stemcell Technologies, Inc.) following the manufacturer's protocol, washed and suspended in PBS. If available, ~1x10^6 PBMCs (in 200 µl) were loaded on columns of the QIA-Amp Blood Kit (Qiagen GmbH) and genomic DNA was isolated following the manufacturer's protocol. DNA was eluted in a final volume of 200 µl. If <1x10^6 mononuclear cells were available, all cells were used for DNA preparation and the elution volume was adjusted accordingly.

Flow cytometric assessment of CAR expression. Frozen PBMCs of selected patients were thawed and flow cytometry (FC) was performed as recently described (17). In brief, CD19 CAR-expressing T cells were determined using the CD19 CAR detection reagent Biotin (cat. no. 130115965; Miltenyi Biotec GmbH) following the manufacturer’s protocol. In brief, PBMCs were washed with FC buffer [PBS (Gibco, Thermo Fisher Scientific)] containing 2% fetal bovine serum (MilliporeSigma) and resuspended in 100 µl FC buffer. Cells were stained with CD19 CAR Detection Reagent Biotin for 10-15 min at RT, washed twice with FC buffer and stained with anti-CD45 Vioblue, anti-CD3 FITC and anti-biotin

| Table I. Characteristics of patients treated with CAR T cells. |
| --- |
| **UPN #** | **Age, years/sex** | **Institution administering CAR T** | **CAR T product/entity** | **Prior therapy lines** | **Bridging therapy** | **Status prior to CAR T therapy** | **CRS grade** | **ICANS grade** | **Best response** |
| 001 | 41/M | UKHD | Axi-cel/DLBCL | 3 | Yes | PD | I | III | PR |
| 002 | 56/M | UKHD | Axi-cel/DLBCL | 3 | Yes | PD | I | - | PR |
| 003 | 40/F | UKHD | Axi-cel/DLBCL | 4 | Yes | PD | I | III | CR |
| 004 | 58/M | UKHD | Axi-cel/DLBCL | 3 | Yes | SD | - | - | SD |
| 005 | 55/M | UKHD | Axi-cel/DLBCL | 3 | Yes | SD | I | - | PR |
| 006 | 53/M | UKE | Axi-cel/DLBCL | 4 | Yes | PD | I | I | CR |
| 007 | 44/M | UKE | Axi-cel/DLBCL | 4 | Yes | PD | III | II | CR |
| 008 | 58/M | UKE | Axi-cel/DLBCL | 8 | Yes | SD | - | - | SD |
| 009 | 52/F | UKE | Axi-cel/DLBCL | 3 | No | PD | II | I | CR |
| 010 | 69/M | UKE | Axi-cel/DLBCL | 4 | Yes | CR | III | - | CR |
| 011 | 66/M | UKHD | Tisa-cel/DLBCL | 5 | Yes | SD | I | - | SD |
| 012 | 49/M | UKHD | Tisa-cel/DLBCL | 3 | No | PR | - | - | SD |
| 013 | 71/M | UKHD | Tisa-cel/DLBCL | 4 | Yes | PD | II | - | PR |
| 014 | 57/M | UKHD | Tisa-cel/DLBCL | 4 | Yes | PD | I | II | PR |
| 015 | 67/M | UKHD | Tisa-cel/DLBCL | 4 | Yes | CR | I | - | CR |
| 016 | 10/M | UKE | Tisa-cel/ALL | 3 | No | PD | I | - | CR |
| 017 | 59/F | UKE | Tisa-cel/DLBCL | 4 | Yes | PD | IV | - | n.e./TRM |
| 018 | 51/M | UKE | Tisa-cel/DLBCL | 3 | Yes | SD | - | - | PR |
| 019 | 67/F | UKE | Tisa-cel/DLBCL | 7 | Yes | PR | I | - | SD |
| 020 | 59/M | UKE | Tisa-cel/DLBCL | 2 | Yes | PR | II | - | CR |

ALL, acute lymphoblastic leukemia; axi-cel, axicabtagene ciloleucel; CAR T, chimeric antigen receptor T cells; CR, complete remission; CRS, cytokine release syndrome; DLBCL, diffuse large B cell lymphoma; F, female; M, male; ICANS, immune effector cell-associated neurotoxicity syndrome; n.e., not evaluable; PR, partial remission; PD, progressive disease; SD, stable disease; tisa-cel, tisagenlecleucel; TRM, treatment-related mortality; UKE, University Medical Center Hamburg-Eppendorf; UKHD, Heidelberg University Hospital; UPN, unique patient number.
phycoerythrin (cat. no. 130110951; Miltenyi Biotec GmbH) for 10 min at RT. After washing with FC buffer, cells were resuspended in 500 µl FC buffer supplemented with Cytofix reagent (BD Biosciences) and subsequently analyzed on a FACS Canto Analyzer (BD Biosciences). At least 125,000 cells were analyzed in the lymphocyte gate to ensure high accuracy. Dead cells were excluded using a fixable viability dye (eFluor 506; Ebioscience; Thermo Fischer Scientific, Inc.). Results were analyzed using FlowJo software, version 10.6.2 (BD Biosciences).

Statistical analysis. Copy numbers of individual samples measured using qPCR and dPCR were compared: qPCR results were set as 100% and the relative difference of the corresponding dPCR result to qPCR was calculated. Two-tailed Pearson statistics with a confidence interval of 95% were applied to determine correlation coefficients ($R^2$) between data-points obtained with qPCR and dPCR. A correlation was considered statistically significant if $P<0.05$. For statistical analyses, GraphPad Prism, version 8.4.3 (GraphPad Software, Inc.) was used.

Results

Response and toxicity in patients treated with CAR T cells. The copy numbers in 113 gDNA samples of 20 patients treated with axi-cel [n=10, five patients per institution (Fig. 1)] and tisa-cel [n=10, five patients per institution (Fig. 2)] were assessed by qPCR and dPCR. The patient data are summarized in Table I. Of the patients treated with tisa-cel, nine patients were treated for DLBCL and one for ALL [unique patient no. (UPN) #016]. Most patients (n=16) were male, the median age of the treated patients was 56.5 years (range, 10-71 years), and patients had received 2-7 prior treatment lines. The majority of patients (n=17) received bridging therapy between lymphodepletion and CAR T cell administration due to a high burden of the hematologic disease or progressive disease (PD). Of those patients, four patients achieved complete remission (CR, n=2) or partial remission (PR, n=2), five patients displayed stable disease (SD) and eight patients had PD despite treatment. Of the three patients that did not receive any bridging therapy, one patient had PR and two patients PD prior CAR T cell treatment. Following CAR T cell administration, 16 patients developed CRS with 3 cases of high-grade CRS (>grade III CRS). ICANS was observed in 6 patients, with high-grade ICANS (>grade III ICANS) evident in 2 patients. Peak levels of CAR T cell copies ranged between 43 and 159,304 copies/µg PBMC DNA. High-grade ICANS was observed in patients with high peak CAR T cell expansion (UPN#001 and #003).

One patient (UPN#017) died within 1 week after CAR T cell treatment due hemophagocytic lymphohistiocytosis/macrophage activation syndrome. The remaining 19 patients were evaluable for assessment of clinical response: 14 patients (74%) responded to treatment, with 8 patients (42%) achieving CR and 6 patients PR (32%) as their best response. SD was observed in 5 patients (26%). Those patients with the lowest CAR T cell expansion [UPN#008 (axi-cel) and UPN#012 (tisa-cel)] did not respond to treatment.

Comparison of qPCR and dPCR for CAR T cell quantification. For all analyzed patient samples, qPCR and dPCR provided highly similar, overlapping logarithmic curves of CAR vector copies/µg PBMC gDNA over time (Figs. 1 and 2). Data sets obtained for each patient with qPCR and dPCR displayed a high degree of correlation with statistical significance for all measurements (Table II). For patient samples with low CAR T cell expansion levels (i.e. UPN #008, #012 and #018; maximum CAR T cell levels <5,000 copies/µg PBMC gDNA), a statistically significant correlation persisted ($R^2>0.78; P<0.05$), reaffirming the comparability of qPCR and dPCR even at low CAR T cell levels. When copy numbers of individual samples were compared by relating dPCR to qPCR results (qPCR set as 100%), the mean quantification results of dPCR were 70±34%, i.e. a mean relative difference of -30% from...
qPCR was observed for dPCR (Fig. 3). Indeed, copy numbers determined using dPCR were lower for almost all measured samples (Figs. 1 and 2). This observation was independent of the dPCR (axi‑cel or tisa‑cel) assay used. Finally, the numbers of CAR‑expressing T cells were assessed by FC for patients treated with axi‑cel and tisa‑cel. FC was retrospectively performed for UPN#009 (axi‑cel) and UPN#020 (tisa‑cel) on PBMCs frozen at 5 different time‑points after CAR T cell administration (Figs. 4 and S1). CAR T cell numbers were determined per µl blood and set in relation to the data obtained by digital PCR for the same patients. As evident from Fig. 4, a high convergence of CAR T cell numbers determined with either method was observed. Of note, a resurgence of CAR T cell numbers as seen in UPN#009 at day 35 was detected by all three methods‑FC, dPCR and qPCR (Figs. 1 and 4). These data are in line with previous observations by our group on the high concordance of PCR‑ and FC‑based quantification (18).

Discussion

CAR T cells as cellular products display variable pharmaco‑kinetic and pharmacodynamic profiles that depend not only on patient‑specific characteristics but also on the administered CAR T cell dose, lymphodepletion therapy and targeted disease (25). Engraftment, expansion and persistence of CAR T cells have important clinical and therapeutic implications (10,11,14,26‑28). Hence, assessing CAR T cell kinetics after CAR T cell treatment is of crucial importance for patient follow‑up. Also, given that CAR genes are stably integrated into the T cell genome via viral vectors, CAR T cells are classified as gene therapy medicinal products (GTMPs). Hence, precise tools to assess vector copy numbers in CAR T cell products are important to ensure GTMP product quality and patient safety.

The present study compared qPCR (19,20) and dPCR (17,18), two broadly applicable quantification assays for monitoring CD19‑targeting CAR T cells established and validated at independent laboratories and institutions.

Both methods target the FMC63‑based scFv incorporated within CD19‑directed CAR T cells that are commercially available in Europe, i.e. axi‑cel, tisa‑cel and brexu‑cel. Although the present study did not formally include patients treated with brexu‑cel, in our experience, quantification by qPCR and dPCR is also suitable for brexu‑cel monitoring (data not shown), given that both products are composed of the same CAR construct and differ only with regards to manufacturing.

When compared to traditional qPCR approaches such as the absolute copy number method, qPCR, i.e. SCG‑DP‑PCR and dPCR, offer methodological advantages and simplify CAR T cell quantification, e.g. by operating independently from calibrator samples or standards (17‑20). While SCG‑DP‑PCR was specifically developed to exclude the requirement for calibrator and standard samples, dPCR intrinsically does not rely on calibrators or standards. Independence from these samples economizes material and time resources, minimizes procedure parameters and simplifies mathematical analysis. Consequently, technical complexity of CAR T cell quantification is reduced. qPCR and dPCR independently fulfill the requirements for Good Clinical Laboratory Practice for CAR quantification (29) and are highly suitable for being established in other clinical and diagnostic laboratories due to easy technical transfer and implementation. Transfer of qPCR and dPCR to other laboratories is supported by a transparent procedural description: For SCG‑DP‑PCR, all PCR oligo sequences are published [(19,20), see also materials and methods section], and for dPCR, all required supplements are available as a commercialized, ready‑to‑use assay kit [(17,18), see also materials and methods section].

qPCR and dPCR provided very similar quantification results when measuring axi‑cel and tisa‑cel levels; the resulting high levels of concordance of CAR T cell kinetics assessed with both methods underlines their equal precision.
This is to be expected, since qPCR and dPCR are based on the same amplification and signal-generation principle, i.e. the hydrolysis probe technique. However, lower dPCR values when compared to qPCR were obtained for almost all tested samples, by a mean magnitude of 30%. Compared to the qPCR approach that applies real-time measurement of the signal generated from PCR products in a reaction cycle when a detection threshold is reached, dPCR fractionates samples in smallest portions with an endpoint detection of every sample fraction. This diverse detection principle, as well as differing assay preparation steps, primer/probe sets and analytical procedures, may have resulted in the observed variations. However, patterns of CAR T cell in vivo kinetics assessed by the two methods were identical, making the differences clinically irrelevant.

PCR-based approaches for quantification amplify small vector fragments integrated within genomic DNA and do not necessarily provide information on the functional expression of the detected CAR. CAR T cell numbers obtained by dPCR and FC were compared for two representative patients, one treated with axi-cel and one with tisa-cel, at five different time-points post-infusion. Convergence of the data obtained with the different detection methods was observed. (Minor) differences were to be expected, since the FC analyses were performed on previously frozen samples. It has been established that cryopreservation may not only lead to reduced viability, but also has an impact on the expression of different proteins/markers in T cells (30). PCR-based approaches, in turn, are less prone to variations in sample quality, i.e. fresh and intact cells, when compared to FC. In addition, FC-based approaches depend on the target population size, as well as total event counts, and are considered to be less sensitive when compared to PCR-based methods (31). In any case, CAR T cell expansion and persistence strongly depend on the growth signal provided by the CAR. Therefore, the survival of transgenic cells not expressing the CAR is unlikely. Accordingly, high correlation levels of CAR quantification data obtained by PCR-based approaches determining the transgene at the genomic level and FC detecting the CAR protein on the CAR T cell surface have been reported by our group (18,32) and others (10).

In the clinical setting, both methods are highly useful: Response to treatment was not observed in patients displaying the lowest CAR T cell expansion. This confirms previous findings by our group that low CAR T cell expansion is associated with limited clinical efficacy (16,17). With regard to toxicity, the present study observed that high-grade ICANS developed more frequently in patients with high CAR T cell expansion, again in line with a previous study by our group (20). However, and as previously reported (11), no association of CRS with CAR T cell expansion was determined.

### Table II. Correlation and statistical significance of data points obtained with qPCR and dPCR.

| UPN # | Time-points, n | R²  | P-value |
|-------|----------------|-----|---------|
| 001   | 5              | 0.999 | <0.0001 |
| 002   | 6              | 1    | <0.0001 |
| 003   | 5              | 1    | <0.0001 |
| 004   | 6              | 0.985 | <0.0001 |
| 005   | 11             | 0.999 | <0.0001 |
| 006   | 5              | 0.993 | 0.0003  |
| 007   | 5              | 0.996 | <0.0001 |
| 008   | 5              | 0.990 | 0.0004  |
| 009   | 5              | 1    | <0.0001 |
| 010   | 3              | 0.999 | 0.0162  |
| 011   | 9              | 0.999 | <0.0001 |
| 012   | 5              | 0.802 | 0.0398  |
| 013   | 6              | 0.994 | <0.0001 |
| 014   | 8              | 0.999 | <0.0001 |
| 015   | 5              | 1    | <0.0001 |
| 016   | 7              | 0.998 | <0.0001 |
| 017   | 2              | n. a. | n.a.    |
| 018   | 6              | 0.779 | 0.0199  |
| 019   | 5              | 0.994 | 0.0002  |
| 020   | 4              | 0.998 | 0.0008  |

Chimeric antigen receptor T cell frequencies at distinct time-points obtained with qPCR and dPCR (axicabtagene ciloleucel, n=56; tisagenlecleucel, n=57) correlated significantly (R²=0.9846). All correlations were statistically significant. In UPN#017, correlation analysis was not performed as only 2 time-points were measured. P<0.05 was considered to indicate a statistically significant correlation. UPN, unique patient number; R², correlation coefficient; n.a., not available; qPCR, quantitative PCR; dPCR, digital droplet PCR.
Treatment with axi-cel carrying CD28 as a costimulatory domain within the CAR construct resulted in higher peak expansion of CAR T cells and side effects were more common in patients treated with axi-cel. Even though based on small patient numbers, this observation is in accordance with previous studies indicating that CD28 is associated with the promotion of the differentiation of CAR T cells into effector CAR T cells with short-lived glycolysis-based metabolism, resulting in rapid and robust CAR T cell expansion (33-35). By contrast, 4-1BB contained as a costimulatory domain within tisa-cel mediates a central memory CAR T cell phenotype with slower expansion, diminished exhaustion and longer CAR T cell persistence (10,33,36-38).

In conclusion, the present study confirmed the validity of qPCR and dPCR for precise CAR T cell quantification and demonstrated that both approaches are comparable and suitable to monitor CD19-directed CAR T cell kinetics. qPCR, i.e. SCG-DP-PCR, and dPCR contribute to the elucidation of the association of CAR T cell kinetics with treatment response and toxicity and are important diagnostic tools to ensure patient safety, enable comprehensive patient follow-up and guide therapeutic decisions in treated patients. In addition, providing dependable real-world data based on the analysis of numerous patients by precise, fast and easily applicable CAR T cell monitoring assays is indispensable for improving the understanding of CAR T cell therapy.

Acknowledgements

The authors thank Mr. Sascha Langner and Ms. Madelaine Bordt at the UKHD Good Manufacturing Practice (GMP) Core facility for technical assistance. We are indebted to Dipl.-Ing. Regine Thiele, Mrs. Melanie Lachmann and Mrs. Julia Spötter from the UKE Core Facility Cytometry and Cell Sorting for their expert support. The authors also thank Mrs. Mandy Hinkelbein at the UKHD GMP Core facility for editing the references.

Funding

MLS was supported by the Olympia Morata Program of the Medical Faculty of Heidelberg (grant no. 09/2019). The Hamburg part of this joint project was partly funded by the Barbara and Wilfried Mohr Stiftung (grant no. DM1669/100).

Availability of data and materials

The datasets used and/or analyzed within this study are available from the corresponding author on reasonable request.

Authors' contributions

AB established and validated the dPCR assays and analyzed and discussed data. AHK was responsible for quality control (QC) of CAR T cell products and discussed data. AK designed the qPCR protocol, performed experiments and acquired, analyzed and discussed data. AS performed leukapheresis of the patients and discussed data. BF designed the study and the dPCR, discussed and interpreted experiments and data and wrote and edited parts of the manuscript. BN performed QC of CAR T cell products and discussed data. CB participated in dPCR development, processed samples, acquired data and designed and organized the study. CMT, FAA, IM and NK treated patients and interpreted and discussed data. KR identified target sequences for dPCRs, discussed the study design and interpreted and analyzed data. LW performed QC of CAR T cell products and discussed data. MLS treated patients and discussed experiments, data and the study design. MS designed the study and treated patients, and discussed and interpreted experiments and data. PD treated patients and interpreted and discussed experiments and data. SZ performed dPCRs analyses and acquired and analyzed data. All authors revised the manuscript. All authors edited the manuscript and approved the final version of the manuscript for publication. All authors agreed to be accountable for all aspects included in this work. MLS, AK and BF checked and approved the authenticity of the raw data.
Ethics approval and consent to participate

The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Ethics Committees of the two institutions (no. S-254/2016 at UKHD Heidelberg and no. PV7091 at UKE Hamburg, Germany).

Patient consent for publication

Informed consent including consent for publication was obtained from all patients involved in the study prior to CAR T cell treatment.

Competing interests

AS is a co-founder and part-time employee of TolerogenixX Ltd. BF has performed consultancy work for Celgene/BMS. CMT received research support from Bayer AG and is an Advisory Board member of Pfizer and Janssen-Cilag GmbH. CMT has also received grants and/or investigational medicinal products from Pfizer, Daichi Sankyo and BioInfiniteRx. FAA has performed consultancy work for Celgene/BMS and is an Advisory board member of Kite/Gilead, Celgene/BMS, Novartis and Janssen. NK has received honoraria from Celgene/BMS, Kite/Gilead, Novartis and Janssen. MLS has performed consultancy work for Kite/Gilead and Takeda, and is an Advisory Board member of Kite/Gilead. MS has received research grants from Apogenex, Hexal and Novartis, and is an Advisory Board member of MSD. MS is also a (co-)principal investigator of clinical trials for MSD, GSK, Kite and BMS, and is a co-founder and a shareholder of TolerogenixX Ltd. PD has performed consultancy work for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser and Roche. The dPCR assay used in the present study was made available as ‘Expert Design Assays’ by Bio-Rad Laboratories, Inc. based on an agreement between UMC Hamburg-Eppendorf and Bio-Rad Laboratories, Inc; in accordance with the German law on employee inventions, BF, AB, CB and KR received compensation payments. Note that Bio-Rad Laboratories, Inc. was not involved in the study design, collection, analysis or interpretation of the data, or in the writing of this paper. None of the mentioned sources supported the work described within this manuscript. The remaining authors have no competing interests to declare.

References

1. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR and Forman SJ: Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16: 1245-1256, 2010.
2. Savolado B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bolland CM, Gee AP, Mei Z, et al: CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121: 1822-1826, 2011.
3. Grupp S, Hu ZH, Zhang Y, Keating A, Pulisperi MA, Philips C, Margossian SF, Rosenthal J, Salzberg D, Schiff DK, et al: Tisagenlecleucel Chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory children and young adults with acute lymphoblastic leukemia (ALL): Real world experience from the center for international blood and marrow transplant research (CIBMTR) and cellular therapy (CT) registry. Blood 134: 2619-2619, 2019.
4. Jaglowski S, Hu ZH, Zhang Y, Kamdar M, Ghosh M, Lulla P, Sasine J, Perales MA, Hematti P, Nikiforow S, et al: Tisagenlecleucel Chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell lymphoma (DLBCL): Real world experience from the center for international blood & marrow transplant research (CIBMTR), cellular therapy (CT) registry. Blood 134: 766-766, 2019.
5. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Gobadi A, Lin Y, Daihiya S, Lunnning M, Lekakis L, Reagan P, et al: Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T Consortium. J Clin Oncol 38: 3119-3128, 2020.
6. Pasquini MC, Locke FL, Herrera AF, Siddiqi T, Gobadi A, Komanduri KV, Hu ZH, Dong H, Hematti P, Nikiforow S, et al: Post-marketing use outcomes of an Anti-CD19 Chimeric antigen receptor (CAR) T-cell therapy, Axicabtagene Ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US). Blood 134: 764-764, 2019.
7. European Medicines Agency: Yescarta-Axicabtagene Ciloleucel. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta.
8. European Medicines Agency: Kymriah-tisagenlecleucel. https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah.
9. European Medicines Agency: Tecartus-Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus.
10. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez Z, Lacey SF, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371: 1517-1517, 2014.
11. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Oluwole OO, Siddiqi T, Lin Y, et al: Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377: 2531-2544, 2017.
12. Turtle CJ, Hay KA, Hanafi LA, Li D, Cherial S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, et al: Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol 35: 3010-3020, 2017.
13. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al: Tisagenlecleucel and induction of molecular remission in B-cell acute lymphoblastic leukemia. N Engl J Med 378: 439-449, 2018.
14. Schuster SJ, Bishop MR, Tam CS, Waller EB, Borchmann P, McGuirk JP, Jüger U, Jaglowski S, Westin JR, et al: Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380: 45-56, 2019.
15. Locke FL, Gobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, et al: Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial. Lancet Oncol 20: 31-42, 2019.
16. Ayuk FA, Berger C, Badbaran A, Zabelina T, Sonntag T, Riecken K, Geffken M, Wichmann D, Frenzel C, Thayssen G, et al: Axicabtagene ciloleucel in vivo expansion and treatment outcome in an aggressive B-cell lymphoma in a real-world setting. Blood Adv 5: 2523-2527, 2021.
17. Fehse B, Badbaran A, Berger C, Sonntag T, Riecken K, Geffken M, Kröger N and Ayuk FA: Digital PCR assays for precise quantification of CD19-CAR-T cells after treatment with axicabtagene ciloleucel. Mol Ther Methods Clin Dev 16: 31-42, 2021.
20. Schubert ML, Kunz A, Schmitt A, Neuber B, Wang L, Hückelhoven-Krauss A, Langner S, Michels B, Wick A, Daniel V, et al: Assessment of CAR T cell frequencies in axicabtagene ciloleucel and tisagenlecleucel patients using duplex quantitative PCR. Cancers 12: 2820, 2020.

21. Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Lin J, Hoos A, Barrington SF and Armand P: Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128: 2489-2496, 2016.

22. Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, Larson RA, Lee SJ, Murphy SB, O'Brien S, et al: End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109: 1810-1816, 2007.

23. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et al: ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25: 625-638, 2019.

24. Sequence of the FMC63‑28Z receptor protein gene. Available from: https://www.ncbi.nlm.nih.gov/nuccore/HM852952.1.

25. Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, et al: Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8: 355ra116, 2016.

26. Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, et al: Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv 4, 560-572, 2020.

27. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, et al: Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv 4, 560-572, 2020.

28. Ayuk F, Fehse B, Janson D, Berger C, Riecken K and Kröger N: Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A. Haematologica 105: 322-324, 2020.

29. Hu Y and Huang J: The chimeric antigen receptor detection toolkit. Front Immunol 11: 1770, 2020.

30. Zhang W, Nilles TL, Johnson JR and Margolick JB: The effect of cellular isolation and cryopreservation on the expression of markers identifying subsets of regulatory T cells. J Immunol Methods 431: 31-37, 2016.

31. Demaret J, Varlet P, Traut J, Beauvais D, Grossemey A, Hégo F, Yakoub-Agha I and Labalette M: Monitoring CAR T-cells using flow cytometry. Cytometry B Clin Cytom 100: 218-224, 2021.

32. Schanda N, Sauer T, Kunz A, Hückelhoven-Krauss A, Neuber B, Wang L, Hinkelbein M, Sedloev D, He B, Schubert ML, et al: Sensitivity and specificity of CD19.CAR-T cell detection by flow cytometry and PCR. Cells 10: 3208, 2021.

33. Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, et al: Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells. Immunity 44: 380-390, 2016.

34. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olives S, Gonzalez N, Smith DD, Forman SJ, Jensen MC and Cooper LJ: CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66: 10995-1004, 2006.

35. Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G and Brenner MK: Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20: 1819-1828, 2006.

36. Long AH, Haso WM, Shern JF, Wanhaien KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al: 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21: 581-590, 2015.

37. Zhao Z, Condomines M, van der Stegen SJ, Perna F, Kloss CC, Gunset G, Plotkin J and Sadelain M: Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Discov 8: 958-971, 2018.

38. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, et al: Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17: 1453-1464, 2009.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.